Orencia Gains Psoriatic Arthritis Approval in Europe
Patients demonstrated improved disease response in 2 clinical trials.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
SUBSCRIBE: eNewsletter
Expanded role for MRI and 2 recently approved treatment options. (©Gemalbarra/Shutterstock.com)
Patients demonstrated improved disease response in 2 clinical trials.
In this slideshow, we highlight newly released treatment recommendations for rheumatic disease patients undergoing total hip or total knee arthroplasty.
Rheumatic patients are more prone to complications post knee and hip surgery. Two physician associations have penned new treatment guidelines.
EULAR 20017: Despite the use of biologic therapy, pain ranging from mild to severe is a persistent problem for psoriatic arthritis patients, researchers reported at EULAR 2017.
Innate lymphoid cells have a clear role in rheumatic disease and its related inflammatory process.
Clinical trial shows that switching from the infliximab originator to its biosimilar does not compromise safety or effectiveness of treatment.
A history of having taken biologics affects whether patients will adhere to prescribed TNFi therapy, researchers show.
From skin to joint issues, the list of symptoms associated with psoriatic arthritis is long and not every patient exhibits the same symptoms. In this slideshow, we highlight PsA symptoms and treatments.
There are two types of PsA patients: Biologic naïve patients who take medication persistence seriously and patients who've given up due to a history of failed TNFi therapy.
To reduce risks while improving quality of life, a comprehensive care approach for psoriatic arthritis patients requires the recognition of treatment risks and treatment options.